CHR-2797: An antiproliferative aminopeptidase inhibitor that leads to amino acid deprivation in human leukemic cells

Cancer Research

Volumn 68, Issue 16, 2008, Pages 6669-6679

  Krige, David ^a,b   Needham, Lindsey A ^a,b   Bawden, Lindsay J ^a,b   Flores, Nicolas ^a   Farmer, Hannah ^a,h   Miles, Lauren E C ^a   Stone, Erica ^a   Callaghan, Juliana ^a   Chandler, Stephen ^b,f   Clark, Vanessa L ^a   Kirwin Jones, Patricia ^a   Legris, Valérie ^a   Owen, Jo ^a   Patel, Thakor ^a   Wood, Steve ^b   Box, Gary ^c   Laber, David ^b,d   Odedra, Rajesh ^b,d   Wright, Annette ^b   Wood, L Michael ^b,e   Eccles, Suzanne A ^c   Bone, Elisabeth A ^a,b   Ayscough, Andrew ^b,g   Drummond, Alan H ^a,b   more..

^a Chroma Therapeutics Ltd   (United Kingdom)

^b British Biotech Pharmaceuticals Ltd   (United Kingdom)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d ASTRAZENECA   (United Kingdom)

^e Serentis Pharma ^*

^f Takeda Pharmaceuticals   (United Kingdom)

^g QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^h UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

[[(HYDROXYCARBAMOYLMETHYL) 4 METHYLPENTANOYLAMINO] 2 PHENYLETHANOIC ACID CYCLOPENTYL ESTER]; [[(HYDROXYHYDROXYCARBAMOYLMETHYL) 4 METHYLPENTANOYLAMINO] 2 PHENYLETHANOIC ACID CYCLOPENTYL ESTER]; [[(HYDROXYHYDROXYCARBAMOYLMETHYL) 4 METHYLPENTANOYLAMINO] 3,3 DIMETHYLBUTANOIC ACID CYCLOPENTYL ESTER]; [[(HYDROXYHYDROXYCARBAMOYLMETHYL) 4 METHYLPENTANOYLAMINO] 3,3 DIMETHYLBUTANOIC ACID]; [[[(HYDROXYHYDROXYCARBAMOYLMETHYL) 4 METHYLPENTANOYLAMINO] 2 PHENYLETHANOIC ACID]]; AMINO ACID TRANSFER RNA LIGASE; AMINO ACID TRANSPORTER; ANTINEOPLASTIC AGENT; BATIMASTAT; BESTATIN; CHR 2797; CHR 3204; CHR 5346; CHR 5515; CHR 79888; ENZYME INHIBITOR; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; PUROMYCIN; SYNTHETIC DNA; UNCLASSIFIED DRUG; 2 (2 (HYDROXY(HYDROXYCARBAMOYL)METHYL) 4 METHYLPENTANOYLAMINO) 2 PHENYLETHANOIC ACID CYCLOPENTYL ESTER; 2-(2-(HYDROXY(HYDROXYCARBAMOYL)METHYL)-4-METHYLPENTANOYLAMINO)-2-PHENYLETHANOIC ACID CYCLOPENTYL ESTER; AMINO ACID; AMINOPEPTIDASE; DRUG DERIVATIVE; GLYCINE; HYDROXAMIC ACID; INITIATION FACTOR 2; LEUCINE; PEPTIDE FRAGMENT; PHENYLALANINE; PMAIP1 PROTEIN, HUMAN; PROTEIN BCL 2; PROTEIN KINASE; PROTEIN SYNTHESIS INHIBITOR; THIOPHENE DERIVATIVE; TUMOR MARKER;

AMINO ACID DEPRIVATION; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CELL STRAIN HL 60; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA MICROARRAY; DRUG BIOAVAILABILITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME SUBSTRATE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MYELOID LEUKEMIA; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN MALNUTRITION; PROTEIN SYNTHESIS; TUMOR CELL; UPREGULATION; ANIMAL; CELL CULTURE; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; IMMUNOBLOTTING; METABOLISM; MOUSE; PATHOLOGY; PHOSPHORYLATION; POLYACRYLAMIDE GEL ELECTROPHORESIS; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

AMINO ACIDS; AMINOPEPTIDASES; ANIMALS; CELL PROLIFERATION; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME INHIBITORS; EUKARYOTIC INITIATION FACTOR-2; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, LEUKEMIC; GLYCINE; HL-60 CELLS; HUMANS; HYDROXAMIC ACIDS; IMMUNOBLOTTING; LEUCINE; MICE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PEPTIDE FRAGMENTS; PHENYLALANINE; PHOSPHORYLATION; PROTEIN KINASES; PROTEIN SYNTHESIS INHIBITORS; PROTO-ONCOGENE PROTEINS C-BCL-2; RATS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; THIOPHENES; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 53049086918     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-6627     Document Type: Article

References (50)

1. Overall CM, Lopez-Otin C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer 2002;2:657-72.
2. Rasheed WK, Johnstone RW, Prince HM. Histone deacetylase inhibitors in cancer therapy. Expert Opin Investig Drugs 2007; 16:659-78.
3. Ichinose Y, Genka K, Koike T, et al. Randomised double-blind placebo-controlled trial of bestatin in patients with resected stage 1 squamous cell carcinoma. J Natl Cancer Inst 2003;95:605-10.
4. Brown PD, Bawden LJ, Miller KM. Use of MMP inhibitors 1999; U.S. Patent, US 5,872,152.
5. Taylor A. Aminopeptidases: structure and function. FASEB J 1993;7:290-8.
6. Albiston AL, Ye S, Chai SY. Membrane bound members of the M1 family: more than aminopeptidases. Protein Pept Lett 2004;11:491-500.
7. Sato Y. Role of aminopeptidase in angiogenesis. Biol Pharm Bull 2004;27:772-6.
8. Saveanu L, Carroll O, Lindo V, et al. Concerted peptide trimming by human ERAP1 and ERAP2 aminopeptidase complexes in the endoplasmic reticulum. Nat Immunol 2005;6:689-97.
9. Scornik OA, Botbol V. Bestatin as an experimental tool in mammals. Curr Drug Metab 2001;2:67-85.
10. Sakuraya M, Tamura J, Itoh K, Kubota K, Naruse T. Aminopeptidase inhibitor ubenimex inhibits the growth of leukaemic cell lines and myeloma cells through its cytotoxicity. J Int Med Res 2000;28:214-21.
11. Ota K, Uzuka Y. Clinical trials of bestatin for leukemia and solid tumours. Biotherapy 1992;4:205-14.
12. Pearson LA, Ayscough AP, Huxley P, Drummond AH. Cytostatic Agents 2002 U.S. Patent, US 6,462,023.
13. Brown PD. Matrix metalloproteinase Inhibitors. Angiogenesis 1998;1:142-54.
14. Constam DB, Tobler AR, Rensing-Ehl A, et al. Puromycin-sensitive aminopeptidase: sequence analysis, expression and functional characterisation. J Biol Chem 1995;270:26931-39.
15. Fafournoux P, Bruhat A, Jousse C. Amino acid regulation of gene expression. Biochem J 2000;351:1-12.
16. Kilberg MS, Pan Y-X Chen H, Leung-Pineda V. Nutritional control of gene expression: how mammalian cells respond to amino acid limitation. Annu Rev Nutr 2005;25:59-85.
17. Schwarzer R, Dames S, Tondera D, Klippel A, Kaufmann J. TRB3 is a PI3-kinase dependent indicator for nutrient starvation. Cell Signal 2006;18:899-909.
18. Watatani Y, Kimura N, Shimizu YI, et al. Amino acid limitation induces expression of ATF5 mRNA at the post-transcription al level. Life Sci 2007;80:879-85.
19. Barbosa-Tessmann IP, Pineda VL, Nick HS, Schuster SM, Kilberg MS. Transcriptional regulation of the human asparagine synthetase gene by carbohydrate availability. Biochem J 1999;339:151-8.
20. Vattem KM, Wek RC. Reinitiation involving upstream ORFs regulates ATF4 mRNA translation in mammalian cells. Proc Natl Acad Sci USA 2004;101:11269-74.
21. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004;18:1926-45.
22. Proud CG. Signalling to translation: how signal transduction pathways control the protein synthetic machinery. Biochem J 2007;403:217-34.
23. Adams JM, Cory S The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007;26:1324-37.
24. Selvakumar P, Lakshmikuttyamma A, Dimmock JR, Sharma RK. Methionine aminopeptidase 2 and cancer. Biochim Biophys Acta 2006;1765:148-54.
25. Lee MD, She Y, Soskis MJ, et al. Human mitochondrial peptide deformylase, a new anti-cancer target of actinonin-based antibiotics. J Clin Invest 2004;114:1107-16.
26. Richon VM, Emiliani S, Verdin E, et al. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci U S A 1998;95:3003-7.
27. Sekine K, Fujii H, Abe F. Induction of apoptosis by bestatin (ubenimex) in human leukemic cell lines. Leukemia 1999; 13:729-34.
28. Grujic M, Renko M. Aminopeptidase inhibitors bestatin and actinonin inhibit cell proliferation of myeloma cells predominantly by intracellular interactions. Cancer Lett 2002;182:113-9.
29. Jousse C, Deval C, Maurin A-C, et al. TRB3 inhibits the transcriptional activation of stress-regulated genes by a negative feedback on the ATF4 pathway. J Biol Chem 2007;282:15851-61.
30. Lopez AB, Wang C, Huang CC, et al. A feedback transcriptional mechanism controls the level of the arginine/lysine transporter cat-1 during amino acid starvation. Biochem J 2007;402:163-73.
31. Ma Y, Hendershot LM. Delineation of a negative feedback regulatory loop that controls protein translation during endoplasmic reticulum stress. J Biol Chem 2003;278:34864-73.
32. Wang H, Kubica N, Ellisen LW, Jefferson LS, Kimball SR. Dexamethasone represses signalling through the mammalian target of rapamycin in muscle cells by enhancing expression of REDD1. J Biol Chem 2006;281:39128-34.
33. Jiang H-Y, Jiang L, Wek RC. The eIF2 kinase pathway facilitates differential GADD45a expression in response to environmental stress. J Biol Chem 2007;282:3755-65.
34. Wek SA, Zhu S, Wek RC. The histidyl-tRNA synthetase-related sequence in the eIF-2α protein kinase GCN2 interacts with tRNA and is required for activation in response to starvation for different amino acids. Mol Cell Biol 1995;15:4497-506.
35. Harding HP, Novoa I, Zhang Y, et al. Regulated translation initiation controls stress-induced gene expression in mammalian cells. Molecular Cell 2000;6:1099-108.
36. Ron D, Walter P. Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol 2007;8:519-29.
37. Gingras AC, Gygi SP, Raught B, et al. Regulation of 4E-BP1 phosphorylation: a novel two step mechanism. Genes Dev 1999;13:1422-37.
38. Beugnet A, Tee AR, Taylor PM, Proud CG. Regulation of targets of mTOR (mammalian target of rapamycin) signalling by intracellular amino acid availability. Biochem J 2003;372:555-66.
39. Sala-Rabanal M, Loo DD, Hirayama BA, et al. Molecular interactions between dipeptides, drugs and the human intestinal H+-oligopeptide cotransporter hPEPT1. J Physiol 2006;574:149-66.
40. Stack CM, Lowther J, Cunningham E, et al. Characterisation of the Plasmodium falciparum M17 leucyl aminopeptidase. A protease involved in amino acid regulation with potential for antimalarial drug development. J Biol Chem 2007;282:2069-80.
41. Dalai S, Klemba M. Roles for two aminopeptidases in vacuolar haemoglobin catabolism in Plasmodium falciparum. J Biol Chem 2007;282:35978-87.
42. Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 2004;4:762-74.
43. Munn DH, Sharma MD, Baban B, et al. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity 2005;22:633-42.
44. Scott L, Lamb J, Smith S, Wheatley DN. Single amino acid (arginine) deprivation: rapid and selective death of cultured transformed and malignant cells. Br J Cancer 2000;83:800-10.
45. Kokkinakis DM, Brickner AG, Kirkwood JM, et al. Mitotic arrest, apoptosis, and sensitization to chemotherapy of melanomas by methionine deprivation stress. Mol Cancer Res 2006;4:575-89.
46. Park I-S, Kang S-W, Shin Y-J, et al. Arginine deiminase: a potential inhibitor of angiogenesis and tumour growth. Br J Cancer 2003;89:907-14.
47. Yanagida O, Kanai Y, Chairoungdua A, et al. Human L-type amino acid transporter (LAT1): characterisation of function and expression in tumor cell lines. Biochim Biophys Acta 2001;1514:291-302.
48. Kim SG, Kim HH, Kim HK, et al. Differential expression and functional characterisation of system L amino acid transporters in human normal osteoblast cells and osteogenic sarcoma cells. Anticancer Res 2006; 26:1989-96.
49. Komatsu K, Tsuda M, Tanaka Y, et al. SAR studies of brasilicardin A for immunosuppressive and cytotoxic activities. Bioog Med Chem 2005; 13:1507-13.
50. Usui T, Nagumo Y, Watanabe A, et al. Brasilicardin A, a natural immunosuppressant, targets amino acid transport system L. Chem Biol 2006;13:1153-60.